Citation: Williams, Rachel C., Skelton, Andrew, Todryk, Stephen, Rowan, Andrew, Preshaw, Philip and Taylor, John (2016) Leptin and Pro-Inflammatory Stimuli Synergistically Upregulate MMP-1 and MMP-3 Secretion in Human Gingival Fibroblasts. PLoS ONE, 11 (2). e0148024. ISSN 1932-6203

Published by: Public Library of Science

URL: https://doi.org/10.1371/journal.pone.0148024
<https://doi.org/10.1371/journal.pone.0148024>

This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/id/eprint/26288/

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University’s research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: http://nrl.northumbria.ac.uk/policies.html

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher’s website (a subscription may be required.)
Leptin and Pro-Inflammatory Stimuli Synergistically Upregulate MMP-1 and MMP-3 Secretion in Human Gingival Fibroblasts

Rachel C. Williams¹,4, Andrew J. Skelton²,3, Stephen M. Todryk⁵, Andrew D. Rowan²,4, Philip M. Preshaw¹,4, John J. Taylor¹,4*

¹ Centre for Oral Health Research, Newcastle University, Newcastle upon Tyne, United Kingdom, 2 Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, 3 Bioinformatics Support Unit, Newcastle University, Newcastle upon Tyne, United Kingdom, 4 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 5 Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Abstract

Introduction

Gingival fibroblast-mediated extracellular matrix remodelling is implicated in the pathogenesis of periodontitis, yet the stimuli that regulate this response are not fully understood. The immunoregulatory adipokine leptin is detectable in the gingiva, human gingival fibroblasts express functional leptin receptor mRNA and leptin is known to regulate extracellular matrix remodelling responses in cardiac fibroblasts. We therefore hypothesised that leptin would enhance matrix metalloproteinase secretion in human gingival fibroblasts.

Methods and Results

We used in vitro cell culture to investigate leptin signalling and the effect of leptin on mRNA and protein expression in human gingival fibroblasts. We confirmed human gingival fibroblasts expressed cell surface leptin receptor, found leptin increased matrix metalloproteinase-1, -3, -8 and -14 expression in human gingival fibroblasts compared to unstimulated cells, and observed that leptin stimulation activated MAPK, STAT1/3 and Akt signalling in human gingival fibroblasts. Furthermore, leptin synergised with IL-1 or the TLR2 agonist pam2CSK4 to markedly enhance matrix metalloproteinase-1 and -3 production by human gingival fibroblasts. Signalling pathway inhibition demonstrated ERK was required for leptin-stimulated matrix metalloproteinase-1 expression in human gingival fibroblasts; whilst ERK, JNK, p38 and STAT3 were required for leptin+IL-1- and leptin+pam2CSK4-induced matrix metalloproteinase-1 expression. A genome-wide expression array and gene ontology analysis confirmed genes differentially expressed in leptin+IL-1-stimulated human gingival fibroblasts (compared to unstimulated cells) were enriched for extracellular matrix organisation and disassembly, and revealed that matrix metalloproteinase-8 and -12 were also synergistically upregulated by leptin+IL-1 in human gingival fibroblasts.
Conclusions
We conclude that leptin selectively enhances the expression and secretion of certain matrix metalloproteinases in human gingival fibroblasts, and suggest that gingival fibroblasts may have an ECM-degrading phenotype during conditions of hyperleptinaemia (e.g., obesity, type 2 diabetes mellitus, exogenous leptin therapy).

Introduction
Gingival connective tissue is predominantly composed of stromal cells, such as fibroblasts, and a collagen-rich extracellular matrix (ECM). Fibroblasts control the formation and remodelling of the gingival ECM, through regulated expression of ECM components and ECM-remodelling enzymes such as matrix metalloproteinases (MMPs) [1]. Fibrillar collagens are degraded by the collagenolytic MMPs (MMP-1, MMP-8 and MMP-13) [2]. Excessive destruction of ECM proteins, such as collagen, can be irreversible and is a feature of the common, chronic inflammatory disease periodontitis. Therefore, ECM remodelling is tightly regulated [3]. Exogenous pro-inflammatory stimuli such as bacterial lipopolysaccharide (LPS) are implicated in the pathogenesis of periodontitis [4] and up-regulate the expression of several MMPs in human gingival fibroblasts (HGFs) [5]. Additionally, the IL-6 family cytokine oncostatin-M (OSM), and IL-1 synergistically increase the secretion of MMP-1 by human gingival fibroblasts (HGFs) [6].

Obesity and type 2 diabetes mellitus are both positively associated with periodontitis [7], however the molecular mechanisms underpinning this relationship are poorly characterised [8]. The profile of circulating cytokines, growth factors and adipokines is altered in obese individuals and those with type 2 diabetes [9], and HGFs respond to many of these molecules. For example, the adipokine adiponectin partially suppresses IL-1-stimulated IL-6 and IL-8 production by HGFs [10]. Changes in the regulation, interactions and functionality of these mediators may link obesity, diabetes and periodontitis [8]. Circulating levels of the adipokine leptin are proportional to total adipose tissue mass, and the primary functions of leptin are to inform the brain of energy reserves and to regulate energy expenditure [11]. However, leptin also plays roles in angiogenesis, fertility, bone metabolism, immunity, wound repair and haematopoiesis, and is classified as a member of the IL-6 cytokine family [12,13]. Leptin has been detected in the gingiva by immunohistochemistry [14] and HGFs express functional leptin receptor (LEPR) mRNA [15]. Functionally, leptin increases the secretion of IL-6 and IL-8 by HGFs [15]. In this study we examined whether leptin, either alone or in combination with inflammatory mediators, could alter the expression of genes involved in ECM remodelling in HGFs, with a focus on the collagenase MMP-1, and the stromelysin MMP-3. We found that leptin enhanced the secretion of MMP-1 and MMP-3, and in combination with IL-1 synergistically up-regulated MMP-1, MMP-3, MMP-8 and MMP-12 expression by HGFs. Mechanistically, we found that leptin+IL-1-induced MMP-1 expression in HGFs was regulated by MAPK and STAT3 signalling.

Materials and Methods
Reagents and Antibodies
Recombinant human (rh) leptin was from Biotechne (Abingdon, UK). In most experiments rhIL-1α was used as an IL-1 receptor agonist as described previously (Catterall, 2001); rhIL-1β was a gift from Dr Keith Ray (GlaxoSmithKline, Stevenage, UK). In microarray experiments
IL-1β (Biotechne) was used. RhOSM was prepared as described previously [16]. Pam2CSK4 and LPS from *E. coli* strain 0111:B4 were from Invivogen (Source Bioscience, Nottingham, UK). Inhibitors of JNK (SP600125) and ERK (U0126) were from Biotechne, inhibitors of p38 (SB203580), STAT3 (S3-201) and Akt (inhibitor VIII) were from Merck Millipore (Watford, UK). Monoclonal antibodies (Abs) against phospho-STAT1 (Y701), phospho-STAT3 (Y705), STAT-3, phospho-p38 (T180/Y182), phospho-JNK (T183/Y185), phospho-ERK1/2 (T202/ Y204), ERK1/2 and phospho-Akt (S473) were from Cell-Signalling Technologies (New England Biolabs, Hitchin, UK), GAPDH Ab from Merck-Millipore, HRP-conjugated anti-mouse and anti-rabbit Ig Abs from Dako (Ely, UK), IgG2B mouse LEPR and isotype control PE-conjugated Abs from R&D Systems, IgG2A mouse Toll-like receptor (TLR)2 and TLR4 APC-conjugated Abs were from EBioscience (Hatfield, UK), and an isotype control APC-conjugated Ab was from AbD Serotec (Kidlington, UK). Except where indicated, all other reagents were supplied by Sigma-Aldrich (Gillingham, UK).

**HGF isolation and culture**

Primary HGFs were derived from healthy gingival tissue obtained from patients with written informed consent undergoing canine tooth exposure surgery, with ethical approval from the National Research Ethics Service Committee North East (Reference: 07/Q1003/41). The tissue was collected on ice into F-12 Ham’s medium, washed in PBS (both supplemented with 200 U/ml penicillin, 200 μg/ml streptomycin and 80 U/ml nystatin), dissected free of gingival epithelium and cut into 2 mm³ sections. Sections were incubated (5% CO₂ at 37°C) in DMEM (containing 4.5 g/l glucose and supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 10% FBS) to allow HGF outgrowth. HGFs were maintained in DMEM as previously described [17] and examined for morphology and expression of the mesenchymal marker vimentin (Fig 1). Briefly, HGFs were fixed in methanol, then washed in TBS (pH 7.6), prior to incubation with mouse monoclonal anti human vimentin Ab (IgG2b, Clone Vim 3B4) (Dako) or diluent alone (3% FBS/TBS). After washing in TBS, HGFs were incubated in Envision polymer (Dako) for 30 min. HGFs were washed again in TBS before incubation in diaminobenzidine solution (Dako) for 5 min, then counterstained with haematoxylin. Excess diaminobenzidine and haematoxylin were removed by washing in water. HGFs between passages 5 and 9 were serum-starved for 18 h before a 30 min pre-treatment with chemical pathway inhibitors or DMSO (<0.1%), followed by stimulation with leptin (0.1–25 μg/ml), IL-1 (0.05 ng/ml), OSM (5 ng/ml), pam2CSK4 (50 ng/ml) and/or LPS (10 ng/ml) for 24 h as described previously [18–20]. Inhibitors and DMSO were used at concentrations that were empirically demonstrated to have no adverse effect on HGF viability at 24 h (not shown).

**RNA extraction and RT-PCR**

RNA was extracted using commercial kits (GenElute Mammalian Total RNA Miniprep Kit; RNAeasy Mini Kit, Qiagen, Manchester, UK; SideStep Lysis and Stabilization Buffer, Agilent Technologies, Wokingham, UK) and reverse transcribed using the High-Capacity cDNA Reverse Transcription kit (Life Technologies, Paisley, UK). Oligonucleotides and PrimerTime qPCR probes (Integrated DNA Technologies, Glasgow, UK) used for real-time RT-PCR are shown in Table 1. TaqMan assays for RNA polymerase II (RNAP) (*POLR2A* Hs00172187_m1) and Collagen Type 6A3 (*COL6A3* Hs00915125_m1) were from Life Technologies. For real-time RT-PCR, relative gene expression levels were determined in cDNA samples using TaqMan Universal Master Mix (Life Technologies) and the ABI Prism 7900HT sequence detection system (Life Technologies). Expression levels were normalised to RNAP. Primers used for
conventional real-time RT-PCR are shown in Table 2. For RT-PCR, cDNA was amplified using Bio-Mix Red PCR reaction mix (Bioline, London, UK) and analysed on 3.5% agarose gels stained with Gel-Red (Biotium, Cambridge Bioscience, Cambridge, UK) using β2-microglobulin (β2m) or 18S rRNA as a reference gene.

![HGF morphology and vimentin expression](image)
ELISA, flow cytometry and immunoblotting

Culture supernatants from HGFs were analysed for total human MMP-1 and MMP-3 by ELISA (R&D systems) according to the manufacturer’s protocol. These assays measure total MMPs (i.e. both proenzymes and active forms). Expression of LEPR on the cell surface of HGFs was analyzed by flow cytometry. 10,000 gated events were acquired on a FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK). Data were analyzed with WinMDI 2.8 software (Joseph Trotter, The Scripps Research Institute, Purdue University, West Lafayette, IN, USA). Western blotting was performed as described previously [18].

Microarray transcriptional profiling

HGFs from three donors were stimulated with leptin (10 μg/ml) ± IL-1β (0.05 ng/ml) for 24 h in independent experiments and RNA was isolated using a RNeasy Mini Kit. Quality control, RNA amplification, hybridisation onto the HumanHT-12 v4 expression beadchip (Illumina, Little Chesterford, UK) and data generation were performed by Cambridge Genomic Services (Cambridge, UK).

| Table 1. Primer and probe sequences used for real-time RT-PCR. |
| --- |
| Gene | Forward | Reverse | Probe |
| MMP-1 | 5’-AGAGTAGAAGGTGAGCAAAATT-3’ | 5’-CCAAGAGATCGCCGAG TTC-3’ | 5’-FAM-CAGAGGTCACACTCTCACGTTG8TC-3’ |
| MMP-2 | 5’-TGGCGATGATTGATACTCTAT-3’ | 5’-TCTTCCAAGTGTCGAGTCTCAT-3’ | 5’-FAM-CTCTGTTGCTCTATGGC-3’ |
| MMP-3 | 5’-TTCGCGGTGTCTCAAG ATGATAT-3’ | 5’-AAAGGAAAGAGGAGGTA CACAGT T-3’ | 5’-FAM-TGAGCTGTTGCTATGGC-3’ |
| MMP-7 | 5’-CGGGGAGGAGGATGACA TA-3’ | 5’-CAGGGAAGGAGGATA GCA-3’ | 5’-FAM-CCGGGAGGAGGAGGAB CAA-3’ |
| MMP-8 | 5’-CAGCTCTCAAGATGATCATCGA-3’ | 5’-ACGGATGTTGAGTATA GCA-3’ | 5’-FAM-CAGAGAAGATGCTATCGA CAA-3’ |
| MMP-9 | 5’-CGAGTGCTTGGTATGCA CTC-3’ | 5’-GCAAGTCTTGGTATGCA CTC-3’ | 5’-FAM-CTCAAGTGGGACACCTCA CAA-3’ |
| MMP-10 | 5’-GACCTGGGCTTTATG GAGATAT-3’ | 5’-CCCGGGAGGTGCGAAA GT-3’ | 5’-FAM-CTCAGGCAACACCTCA CAA-3’ |
| MMP-12 | 5’-CGGCGGTTGATGACCTCA AACTCA A-3’ | 5’-GTTAGTGACAGCTCAGA CATCAGT T-3’ | 5’-FAM-TTCTGTTGCTCTATGGC-3’ |
| MMP-13 | 5’-CTTCTGAGGTTGTCAGA CACTA A-3’ | 5’-CTTCTGAGGTTGTCAGA CACTA A-3’ | 5’-FAM-CTCAACATTGTTCTTGGT GCTGGCCTGTA-3’ |
| MMP-14 | 5’-AGCCGACATCATGAT CTTCTT-3’ | 5’-CCGACTGGGCTTTATG GAGATAT-3’ | 5’-FAM-CCGACTGGGCTTTATG GAGATAT-3’ |
| TIMP-1 | 5’-GTATAAGGATGGTCTTGTT GACCTCTC-3’ | 5’-GACGGCCTTCTGCAAT TCC-3’ | 5’-FAM-ACCTGCTCATGGAGCAGA GTTCTC-3’ |
| TIMP-2 | 5’-GGGACTGATGAGACCC ACCAGG-3’ | 5’-GAAGGATGAGACCC ACCAGG-3’ | 5’-FAM-ACCTGCTCATGGAGCAGA GTTCTC-3’ |
| TIMP-3 | 5’-CCTCTTCTGCAAT TCC-3’ | 5’-GACGGCCTTCTGCAAT TCC-3’ | 5’-FAM-ACCTGCTCATGGAGCAGA GTTCTC-3’ |

Table 2. Primer sequences used for conventional RT-PCR.

| Gene | Forward | Reverse | Product size |
| --- | --- | --- | --- |
| MMP-3 | 5’-TTCCGCGCTTCGTAAG ATGATAT-3’ | 5’-AAAGGAAAGAGGAGGTA CACAGT T-3’ | 150 bp |
| 18S RNA | 5’-CAGATGGGCTTCAATTA TAATGTTTATG G-3’ | 5’-CTTATCATGTTTCGATAC CAGAGT TACAC-3’ | 85 bp |
| LEPR | 5’-GAGAGTGTTTGGAC 3’ | 5’-CTTATCATGTTTCGATAC CAGAGT TACAC-3’ | 428 bp |
| β2m | 5’-ACCCGACCTGAGAAA ATGAGATAT-3’ | 5’-CTTATCATGTTTCGATAC CAGAGT TACAC-3’ | 425 bp |

doi:10.1371/journal.pone.0148024.t001
doi:10.1371/journal.pone.0148024.t002
Expression datasets were normalised using the robust spline method and principal component analysis was performed in R (Bioconductor, Seattle, WA, USA). Principle component analysis identified that the datasets from one donor were different to the others in one dimension (not shown). This variation was eliminated using ComBat/surrogate variable analysis [21,22]. The Human HT-12 v4 expression beadchip consists of > 47,000 probes and covers 31,000 genes. Differentially expressed genes for selected comparisons were determined as those having a corrected p value of <0.01 (as assessed using Limma with Benjamini-Hochberg correction for multiple comparisons) and a fold change ≥2. Gene ontology (GO) overrepresentation analysis (biological processes only) was performed using the GOstats Bioconductor library in R. The datasets used in this study are deposited in Gene Expression Omnibus (Ref: GSE68685) in accordance with Minimum Information About a Microarray Experiment (MIAME).

Statistical analysis
Statistical analysis was performed using SPSS 15.0. Shapiro-Wilk testing for normality and Levene testing for homogeneity of variance were performed prior to post hoc analyses of parametric and non-parametric data by Student’s t test and Mann Whitney U test respectively. Real-time RT-PCR data were analysed using ΔCt values [23]. P values were corrected for multiple comparisons using the Bonferroni-Holm correction. A P value of <0.05 was considered significant.

Results
Leptin upregulates MMP expression in HGFs
Leptin increased the expression of the collagenase MMP-1 in HGFs in a dose-dependent manner (Fig 2A; Table 3). Similar effects on MMP-1 protein secretion were also observed in HGFs (Fig 2B). This increased MMP-1 secretion was observed in a time-dependent manner (Fig 2C). The collagenase MMP-8 was also upregulated by leptin in HGFs (Table 3). In contrast, the collagenase MMP-13 was not induced by leptin (Table 3). Leptin had no effect on the expression of the gelatinases (MMP-2/MMP-9), the matrilysin MMP-7, the metalloelastase MMP-12 and tissue inhibitor of metalloproteinase (TIMP)-1-3, although most of these genes were expressed basally in HGFs (Table 3). Similarly, leptin had no effect on the expression of the stromelysins MMP-3 and MMP-10 in HGFs; however, the expression levels of MMP-3 were low and not consistently detected in all donors by RT-PCR. MMP-3 protein secretion in HGFs was increased by leptin though the absolute levels of expression were donor-dependent ranging between 51.9±5.2–1760±510 pg/ml (Fig 2D). Leptin increased the expression of the membrane-type MMP-14 in HGFs in a dose-dependent manner (Fig 2E). The related IL-6 family cytokine OSM, but not IL-1, pam2CSK4 or LPS, similarly increased MMP-14 expression (Fig 2F and 2G).

Leptin and IL-1 or pam2CSK4 synergistically upregulate MMP-1 and MMP-3 expression in HGFs
Previous studies have demonstrated that IL-1 regulates MMP-1/3 expression in HGFs [24,25], and that IL-1 and OSM synergistically increase MMP-1 secretion by HGFs [6]. Since we found that IL-1+OSM synergistically increased MMP-1 mRNA levels, and MMP-1 and MMP-3 protein secretion by HGFs (Fig 3), we stimulated HGFs with leptin+IL-1. We observed a synergistic increase in MMP-1 and MMP-3 mRNA levels and protein secretion in HGFs stimulated with leptin+IL-1 (Fig 4A–4D). Leptin+IL-1 did not synergistically regulate the gene expression
Fig 2. Effect of leptin on MMP mRNA and protein synthesis in HGFs. HGFs were stimulated with leptin (0–25 μg/ml) for 24 h; MMP-1 gene expression was assessed by real-time RT-PCR (A) and supernatant MMP-1 concentrations were assessed by ELISA (B). HGFs were stimulated with leptin (10 μg/ml) for 24 h or the indicated durations and supernatant MMP-1 (C) and MMP-3 (D) concentrations were assessed by ELISA. HGFs were stimulated with leptin (0–25 μg/ml) for 24 h and MMP-14 gene expression was assessed by real-time RT-PCR (E). HGFs were stimulated with IL-1α (0.05 ng/ml) or OSM (5 ng/ml) alone, or in combination with leptin (10 μg/ml) (F) and pam2CSK4 (50 ng/ml) or E. coli LPS (10 ng/ml) alone, or in combination with leptin (10 μg/ml) for 24 h (G) and MMP-14 gene expression was determined by real-time RT-PCR. RT-PCR data (fold control) are expressed relative to RNAP. Data (excluding Fig 2D) are presented as mean±SEM.
Leptin Responses in Gingival Fibroblasts

HGF cultures from 3 HGF donors stimulated in independent experiments (n = 4 from each donor). Remaining data (Fig 2D) are expressed as mean±SD from 3 individual HGF donors (n = 4 from each donor). *P<0.05, **P<0.01, ***P<0.001 compared to the unstimulated control at the same time point.

doi:10.1371/journal.pone.0148024.g002

levels of membrane-type MMP-14 (Fig 2F), MMP-2/MMP-9, MMP-7 or TIMP-1 in HGFs (not shown). Next, we stimulated HGFs with leptin in the absence or presence of pam2CSK4 or LPS, to assess synergy between leptin and these TLR agonists. Both TLR2 and TLR4 were expressed on the surface of HGFs (Fig 5). Leptin+pam2CSK4 significantly increased the expression of MMP-1 gene and protein (Fig 4E and 4F respectively) and MMP-3 (Fig 4G) compared to HGFs stimulated with leptin or pam2CSK4 alone. However, the absolute levels of secreted MMP-1 and MMP-3 by leptin+pam2CSK4-stimulated HGFs were donor-dependent, ranging between 3.65±0.32 – >42.0 ng/ml and 0.15±0.01 – 4.06 ±0.16 ng/ml respectively (Fig 4F and 4G). Interestingly, synergy between leptin and LPS for MMP-1 expression in HGFs was also observed but again appeared to be donor-dependent only in one of three donors tested (Fig 4H).

Leptin activates MAPK, STAT and Akt signalling in HGFs

HGFs express cell surface LEPR and the long isoform of the LEPR (Fig 6A). Stimulation of HGFs with leptin, alone or in combination with IL-1 or pam2CSK4, activated multiple signalling pathways (Fig 6B). Leptin activated the MAPK pathway in HGFs, as evidenced by phosphorylation of p38, JNK and ERK (Fig 6B). Leptin and OSM, but not IL-1 or pam2CSK4, induced STAT1 and STAT3 tyrosine phosphorylation in HGFs. Similarly, phosphorylation of Akt (at S473) in HGFs was induced by leptin and OSM, but not IL-1 or pam2CSK4 (Fig 6B).

Multiple signaling pathways control leptin+IL-1-induced MMP-1 expression

To investigate whether these identified signaling pathways regulated the expression of leptin-induced MMP-1, HGFs were cultured in the presence of selective pathway inhibitors. The ERK

| Group            | Gene    | Basal expression | Effect of leptin on mRNA expression | Number of donors tested |
|------------------|---------|------------------|-------------------------------------|-------------------------|
| Collagenase      | MMP-1   | +                | Upregulated at ≥ 10 μg/ml            | 7                       |
|                  | MMP-8   | +                | Upregulated at 10 μg/ml              | 4                       |
|                  | MMP-13  | -                | No effect                            | 4                       |
| Gelatinase       | MMP-2   | +                | No effect                            | 3                       |
|                  | MMP-9   | -                | No effect                            | 3                       |
| Stromelysin      | MMP-3   | +/-              | No effect                            | 4                       |
|                  | MMP-10  | +                | No effect                            | 3                       |
| Matrilysins      | MMP-7   | -                | No effect                            | 3                       |
| Membrane-type MMP| MMP-14  | +                | Upregulated at ≥ 1 μg/ml             | 3                       |
| Other TIMPs      | MMP-12  | +                | No effect                            | 3                       |
| TIMPs            | TIMP-1  | +                | No effect                            | 4                       |
|                  | TIMP-2  | +                | No effect                            | 3                       |
|                  | TIMP-3  | +                | No effect                            | 3                       |

Gene expression was determined by real-time RT-PCR. + indicates basal gene expression in all donors, +/- indicates basal gene expression in some donors, - indicates no basal gene expression in all donors assessed. ‘No effect’ indicates no effect at ≤ 25 μg/ml

doi:10.1371/journal.pone.0148024.l003
Fig 3. Effect of IL-1 and OSM on MMP-1 and MMP-3 production by HGFs. HGFs were stimulated with IL-1α (0.05 ng/ml), OSM (5 ng/ml) or IL-1α+OSM for 24 h. (A) MMP-1 gene expression was assessed by real-time RT-PCR and data (fold control) are expressed relative to RNAP. Supernatant MMP-1 (B) and MMP-3 (C) concentrations were assessed by ELISA. Data are presented as mean+SEM of three donors stimulated in independent experiments (n = 4 for each donor). **P<0.01, ***P<0.001 compared to the unstimulated control at the same time point.

doi:10.1371/journal.pone.0148024.g003
Fig 4. Effect of leptin and IL-1, pam2CSK4 or LPS on MMP-1 and MMP-3 production by HGFs. HGFs were stimulated with leptin (10 μg/ml), IL-1α (0.05 ng/ml) or leptin+IL-1α for 24 h (A-D). HGFs were stimulated with leptin (10 μg/ml), pam2CSK4 (50 ng/ml), or leptin+pam2CSK4 for 24 h (E-G). Inset (G): MMP-3 concentrations in HGFs isolated from donor 3 presented using an amplified scale. HGFs were stimulated with leptin (10 μg/ml), LPS (10 ng/ml) or leptin+LPS for 24 h (H). MMP-1 gene expression was assessed by real-time RT-PCR and data (fold control) are expressed relative to RNAP with the exception of Fig 4C which illustrates MMP-3 and 18S rRNA gene expression as assessed by RT-PCR and visualized on agarose gels. Supernatant MMP-1 concentrations were assessed by ELISA. Data (A, B, D, E) are presented as mean+SEM from 3 HGF donors stimulated in independent experiments (n = 4)
inhibitor U0126 significantly reduced MMP-1 expression in HGFs stimulated with leptin, IL-1 and pam2CSK4 both alone and in combination (Fig 6C). The JNK inhibitor SP600125 and STAT3 inhibitor VI significantly reduced MMP-1 expression in HGFs stimulated with leptin+IL-1 or leptin+pam2CSK4 (Fig 6D and 6E), whilst the p38 inhibitor SB203580 only significantly reduced MMP-1 expression in HGFs stimulated with leptin+IL-1 (Fig 6F). Akt inhibitor VIII at a concentration of 0.3 μM failed to inhibit MMP-1 gene expression in HGFs stimulated with leptin, IL-1 and/or pam2CSK4 for 24 h (not shown). Thus, multiple signaling pathways are involved in mediating leptin-induced MMP-1 expression in HGFs.

Leptin+IL-1 alter the HGF transcriptome towards an ECM-degrading phenotype

In order to assess the extent of genes involved in ECM remodelling altered by leptin+IL-1 in HGFs, we conducted genome-wide transcriptional profiling by microarray. Numerous genes relevant to ECM remodelling were significantly regulated in HGFs by leptin, IL-1 and
Fig 6. Investigation of leptin receptor expression and signalling pathways leading to MMP-1 synthesis in HGFs. Flow cytometry for cell surface leptin receptor expression on unstimulated HGFs (A). Data are representative of similar data from 4 HGF donors. Inset (A): long LEPR isoform (Ob-Rb) and β2m gene expression as assessed by RT-PCR in unstimulated HGFs. Data are representative of similar results from 7 HGF donors. HGFs were stimulated with leptin (10 µg/ml), IL-1 (0.05 ng/ml), pam2CSK4 (50 ng/ml), OSM (5 ng/ml), leptin+IL-1 or leptin+pam2CSK4 for 20 min and lysates immunoblotted with the indicated antibodies including GAPDH as a loading control (B). The blots presented are all derived from the same donor and are representative of similar results from 3 donors stimulated in independent experiments. (C) HGFs were pre-treated with the ERK inhibitor U0126 (7.5 µM), (D) the JNK inhibitor...
leptin+IL-1 compared to unstimulated HGFs (Table 4). Among these genes, the most upregulated by leptin+IL-1 were MMP3 and MMP1, whilst several collagen genes (e.g. COL6A3, COL14A1, COL15A1) were down-regulated by leptin+IL-1 compared to the unstimulated control. Indeed, most of the genes related to ECM remodelling were only significantly regulated in HGFs stimulated with leptin+IL-1 together, rather than these mediators alone, suggesting a synergistic regulation. We found that several GO terms related to ECM remodelling were significantly overrepresented in the differentially expressed gene list for leptin+IL-1-stimulated HGFs compared to unstimulated controls (Table 5).

HGFs from three donors were stimulated with leptin (10 μg/ml), IL-1β (0.05 ng/ml) or leptin+IL-1β for 24 h in independent experiments. RNA was extracted and used for genome-wide expression analysis (Illumina microarray). Genes displayed were significantly differentially expressed after leptin, IL-1 or leptin+IL-1 stimulation compared to unstimulated HGFs. The numbers displayed indicate fold change in stimulated HGFs as compared to unstimulated HGFs. —Indicates no change in gene expression.

These GO terms and example gene were significantly overrepresented in leptin+IL-1-stimulated HGFs compared to unstimulated HGFs. The effect of leptin and IL-1 on the expression of several genes highlighted by transcriptional profiling (MMPs and COL6A3) was confirmed by real-time RT-PCR (Fig 7). Thus, leptin and IL-1 synergistically increased the expression of MMP-3, MMP-8 and MMP-12 in HGFs (Fig 7A–7C). We also confirmed that the expression of COL6A3 was significantly lower in HGFs stimulated with leptin+IL-1 compared to either leptin or IL-1 alone (Fig 7D). Finally, we confirmed that leptin+IL-1 enhanced MMP-14 and MMP-2 expression in HGFs compared to unstimulated cells (Fig 7E and 7F). However, increases in MMP-14 and MMP-2 expression in HGFs were not due to synergy between leptin and IL-1; MMP-14 expression was stimulated by leptin independently of IL-1 (as observed in Fig 2), whilst IL-1 stimulated MMP-2 expression independently of leptin. Although expression of leptin itself by HGFs was detected in the microarrays this was only detected at very low levels and was not influenced by any of the experimental treatments. Similarly, there was no evidence from the microarray experiments for any effect of leptin in IL-1 expression.

Discussion

HGF-mediated ECM remodelling is implicated in the pathogenesis of periodontitis [1], but the role of adipokines in regulating this effect is not fully understood. Leptin upregulates the secretion of IL-6 and IL-8 by HGFs [15] and in the current study we demonstrated for the first time that leptin upregulates MMP-1 and MMP-3 secretion in HGFs, alone and synergistically in combination with IL-1 or pam2CSK4.

Leptin enhances the expression of MMPs in chondrocytes/cartilage [18,26] however, there are no studies concerning leptin-stimulated MMP/TIMP expression in HGFs, or indeed in any human fibroblasts. We demonstrated that the expression of certain MMPs (MMP-1, MMP-3, MMP-8, MMP-14) with different substrate preferences and extracellular locations [3] were upregulated by leptin in HGFs, which indicates that leptin stimulation of HGFs may result in the remodelling of a broad range of ECM components (including fibrillar collagens). While others have found TIMP-1 mRNA and protein expression in HGFs is stimulated by LPS [5,27].
Table 4. Genes functionally related to ECM homeostasis and proteolysis that were differentially expressed in HGFs treated with leptin and/or IL-1.

| Type                          | Symbol | Gene name                                      | Fold change \(\text{leptin+IL-1}\) | Fold change (leptin) | Fold change \(\text{IL-1}\) |
|-------------------------------|--------|-----------------------------------------------|-------------------------------------|----------------------|-----------------------------|
| **MMPs**                      | MMP1   | matrix metallopeptidase 1                     | 13.0                                | -                    | 4.3                         |
|                               | MMP2   | matrix metallopeptidase 2                     | 2.4                                 | -                    | -                           |
|                               | MMP3   | matrix metallopeptidase 3                     | 55.9                                | -                    | 12.1                        |
|                               | MMP8   | matrix metallopeptidase 8                     | 2.5                                 | -                    | -                           |
|                               | MMP12  | matrix metallopeptidase 12                    | 2.0                                 | -                    | -                           |
|                               | MMP14  | matrix metallopeptidase 14                    | 2.0                                 | -                    | -                           |
| **Other metallopeptidases**   | ADAM19 | ADAM metallopeptidase domain 19               | -3.0                                | -2.1                 | -2.6                        |
|                               | ADAMTS1| ADAM metallopeptidase with                      |
|                               |        | thrombospondin type 1 motif, 1                | -                                   | 2.2                  | -                           |
|                               | MME    | membrane metallo-endopeptidase                | 3.3                                 | -                    | 2.3                         |
| **Collagens**                 | COL1A1 | collagen, type XIV, alpha 1                   | -2.2                                | -                    | -                           |
|                               | COL15A1| collagen, type XV, alpha 1                    | -2.1                                | -                    | -                           |
|                               | COL5A1 | collagen, type V, alpha 1                     | -2.0                                | -                    | -                           |
|                               | COL6A3 | collagen, type VI, alpha 3                    | -2.8                                | -                    | -                           |
|                               | COL8A1 | collagen, type VIII, alpha 1                  | -                                   | -                    | 2.7                         |
|                               | COL8A2 | collagen, type VIII, alpha 2                  | -2.0                                | -                    | -                           |
| **Serine proteases**          | DPP4   | dipeptidyl-peptidase 4                        | 2.1                                 | -                    | -                           |
|                               | PLAT   | plasminogen activator, tissue                | 2.6                                 | -                    | -                           |
|                               | PRSS12 | protease, serine, 12                         | -2.4                                | -                    | -                           |
|                               | PRSS23 | protease, serine, 23                         | -6.0                                | -                    | -2.4                        |
| **Endopeptidase inhibitors**  | PI3    | peptidase inhibitor 3, skin-derived          | 8.5                                 | -                    | 2.4                         |
|                               | SLPI   | secretory leukocyte peptidase inhibitor       | 2.5                                 | -                    | -                           |
|                               | TIMP3  | TIMP metallopeptidase inhibitor 3             | -2.3                                | -                    | -                           |
| **Serine protease inhibitors**| KAZALD1| Kazal-type serine peptidase inhibitor         | -2.3                                | -                    | -                           |
|                               | SERPINA3| serpin peptidase inhibitor, clade A,          | 2.3                                 | -                    | -                           |
|                               | SERPINB2| serpin peptidase inhibitor, clade B,          | 2.1                                 | -                    | -                           |
|                               | SERPINB4| serpin peptidase inhibitor, clade B,          | 3.3                                 | -                    | -                           |
|                               | SERPINB7| serpin peptidase inhibitor, clade B,          | 2.0                                 | -                    | -                           |
|                               | SERPING1| serpin peptidase inhibitor, clade G,          | -                                   | 2.0                  | -                           |
|                               | SERPINI1| serpin peptidase inhibitor, clade I,          | -2.3                                | -                    | -                           |
| **Glycoproteins localised to ECM** | EFEMP1| EGF containing fibulin-like extracellular      |
|                               |        | matrix protein 1                              | -                                   | 2.1                  | -                           |
|                               | THBS1  | thrombospondin 1                              | 3.3                                 | -                    | -                           |
|                               | THBS4  | thrombospondin 4                              | -2.0                                | -                    | -                           |
|                               | TNC    | tenascin C                                   | 4.3                                 | -                    | 3.8                         |
| **Proteins localised to ECM**  | LAMA5  | laminin, alpha 5                             | -2.0                                | -                    | -                           |
|                               | LAMB3  | laminin, beta 3                              | 3.1                                 | -                    | -                           |
|                               | MATN2  | matrilin 2                                   | -2.2                                | -                    | -                           |
|                               | MGP    | matrix Gla protein                           | -4.0                                | -                    | -2.9                        |
|                               | NTN4   | netrin 4                                     | -2.2                                | -                    | -                           |
|                               | OGN    | osteoglycin                                  | -2.3                                | -                    | -                           |

(Continued)
we found no differences in TIMP gene expression in HGFs stimulated by leptin, IL-1, OSM, LPS or pam2CSK4 suggesting that leptin could promote ECM remodelling by HGFs by increasing the active MMP:TIMP ratio.

In agreement with previous work investigating cytokine synthesis in HGFs [28,29] we observed that MMP responses to both LPS and pam2CSK4, and leptin-stimulated MMP-3 responses were qualitatively but not quantitatively similar between HGFs from different donors. These differences might be explained by genetic and/or epigenetic differences between individuals although this requires systematic investigation.

We demonstrated that leptin and IL-1 synergistically increase the expression of multiple MMPs (MMP-1, MMP-3, MMP-8, MMP-12) in HGFs. The fold change in MMP-1 expression in leptin+IL-1-stimulated HGFs in this study was approximately 10 times higher than that observed in a previous study in chondrocytes using the same concentrations of leptin and IL-1 [18]. Also, to our knowledge, this is the first report of synergy between leptin and a TLR2 agonist (pam2CSK4) in any primary human cells. These results indicate that the potential for HGF-mediated ECM remodelling may be greatly enhanced under simultaneous hyperleptinaemic

Table 4. (Continued)

| Type                                      | Symbol | Gene name                     | Fold change (leptin+IL-1) | Fold change (leptin) | Fold change (IL-1) |
|-------------------------------------------|--------|-------------------------------|---------------------------|----------------------|--------------------|
| Other ECM components or regulators        | POSTN  | perioistin                    | -2.7                      | -                    | -2.1               |
| of ECM components                         | CSPG4  | chondroitin sulfate proteoglycan 4 | -2.0                      | -                    | -                  |
|                                            | HAS3   | hyaluronan synthase 3         | 2.3                       | -                    | -                  |
|                                            | PLOD2  | procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | 2.8                       | -                    | -                  |
|                                            | VCAN   | versican                      | -2.8                      | -                    | -2.4               |
| Other peptidases or regulators of         | CASP3  | caspase 3, apoptosis-related cysteine peptidase | 2.9                       | -                    | -                  |
| proteolysis                               | CTSL   | cathepsin L                   | 3.3                       | 3.6                  | -                  |
|                                            | LAP3   | leucine aminopeptidase 3      | 2.9                       | -                    | -                  |
|                                            | PCOLCE2  | procollagen C-endopeptidase enhancer 2 | -2.5                      | -                    | -                  |
|                                            | PLUR   | plasminogen activator, urokinase receptor | 2.7                       | -                    | -                  |

doi:10.1371/journal.pone.0148024.t004

Table 5. GO terms relevant to ECM homeostasis and proteolysis are significantly over-represented in HGFs stimulated with leptin and IL-1.

| GO term                                      | Adjusted P value | Example genes up                | Example genes down        |
|----------------------------------------------|------------------|---------------------------------|----------------------------|
| GO:0009611 response to wounding              | 7.66E-18         | PLAT, TNC, CASP3, SERPINB2      | POSTN, NTN4, KAZALD1, LAMA5|
| GO:0030198 extracellular matrix organization | 5.72E-10         | MMP3, MMP1, THBS1, LAMB3, PLOD2, MMP8, HAS3, MMP14, MMP12 | POSTN, NTN4, KAZALD1, LAMA5|
| GO:0043062 extracellular structure           | 5.72E-10         | MMP3, MMP1, THBS1, LAMB3, PLOD2, MMP8, HAS3, MMP14, MMP12 | POSTN, NTN4, KAZALD1, LAMA5|
| organization                                |                  |                                 |                            |
| GO:0022617 extracellular matrix disassembly  | 3.76E-05         | MMP3, MMP1, LAMB3, MMP8, MMP14  | LAMA5                      |
| GO:0032963 collagen metabolic process        | 3.62E-05         | MMP3, MMP1, MMP8, MMP2, MMP14, MMP12 |                            |
| GO:0030574 collagen catabolic process        | 0.000725         |                                 |                            |
| GO:0062547 regulation of peptidase activity  | 0.00176          | PI3, SERPINB4, SLPI, SERPINA3, SERPINB2 | TIMP3, COL6A3, PCOLCE2, SERPINI1|

doi:10.1371/journal.pone.0148024.t005
Fig 7. Confirmation of the microarray dataset by real-time RT-PCR. HGFs were stimulated with leptin (10 μg/ml), IL-1β (0.05 ng/ml) or leptin+IL-1β for 24 h. Real-time RT-PCR was used to assess (A) MMP-3, (B) MMP-8, (C) MMP-12, (D) collagen 6A3 (COL6A3), (E) MMP-14, and (F) MMP-2 gene expression. Data are expressed relative to RNAP and are presented as mean+SEM from three donors stimulated in independent experiments (n = 4 for each donor).

*P<0.05, **P<0.01, ***P<0.001 compared to the unstimulated control at the same time point.

doi:10.1371/journal.pone.0148024.g007
and proinflammatory conditions, which could disturb ECM homeostasis and promote deleterious ECM degradation as is observed in periodontitis. Furthermore, leptin increases MMP-14 protein production and surface expression in primary rat cardiac fibroblasts [30]; similarly, leptin (and OSM) increased MMP-14 expression in HGFs in this study suggesting a role for IL-6 family cytokines in regulating pericellular ECM remodelling by HGFs.

All the short isoforms of the LEPR are expressed at the mRNA level by HGFs [15], including the long LEPR isoform in accordance with the data presented herein. Leptin activates the MAPK, JAK/STAT, and PI3K/Akt signalling pathways in HGFs; these are some of the well characterised signalling responses activated downstream of the long LEPR isoform [31]. Together with the finding that HGFs express cell surface LEPR, these data suggest that HGFs are sensitive and responsive to leptin.

ERK is known to regulate MMP-1 expression in IL-1-stimulated HGFs [32,33], and in leptin-stimulated chondrocytes/cartilage [18,26]. We showed that ERK regulates MMP-1 expression in HGFs stimulated with leptin, IL-1 and pam2CSK4 alone and in combination. Similarly, MAPK and STAT signalling pathways clearly regulate MMP-1 expression in HGFs stimulated by leptin+IL-1 as has been shown in chondrocytes [18]. We also showed that MMP-1 expression stimulated by leptin and pam2CSK4 is regulated by MAPK and STAT signalling. Multiple mechanisms, such as direct binding to the MMP-1 promoter [34,35], crosstalk between signalling pathways [36], and chromatin remodelling [37] could underpin the requirement for STAT3 in regulating MMP-1 expression in HGFs. Additionally, functional redundancy between STAT family members could add another dimension to this mechanism [38]. Interestingly, Akt inhibitor VIII did not inhibit leptin (+IL-1/pam2CSK4)-induced MMP-1 expression by HGFs, which could be attributed to a requirement to use lower concentrations of this inhibitor than other studies [18,39] due to a cytotoxic effect in HGFs (not shown). Together, our results suggest that leptin and pro-inflammatory mediators stimulate specific and coordinated gingival fibroblast signalling events that determine the production of the collagenase MMP-1.

Transcriptional profiling revealed that MMP-8 and MMP-12 were most upregulated in HGFs after stimulation with both leptin and IL-1 together. While MMP-8 in the periodontium is predominantly thought to be neutrophil-derived [40,41], there is evidence that other cells in the periodontium such as plasma cells, ‘macrophage-like cells’, sulcular epithelial cells as well as HGFs synthesise MMP-8 [25,41]. The elastase MMP-12 can activate itself and other MMPs through autolytic processing [42], providing a putative mechanism by which the initial activation of HGF-derived MMPs upregulated by leptin+IL-1 could occur. Interestingly, leptin+IL-1, as compared to leptin or IL-1 alone, synergistically regulated a wide range of genes relevant to ECM remodelling not limited to MMPs including collagens and other enzymes as well as certain cytokines and chemokines (unpublished observations). Studies that investigate the full extent of the HGF phenotype induced by leptin and the functional implications of this, in relation to ECM remodelling and to broader inflammatory responses in the gingiva are clearly required, and may help to address the possible redundancy between leptin and other IL-6 family members (e.g. OSM).

Circulating leptin concentrations are proportional to adipose tissue mass, and as such leptin has been shown to indicate organismal energy status to several tissues/organs [11] and also influence the immunocompetence of leukocytes [43]. We hypothesise that leptin could serve to inform HGFs of the energy status of an organism, thereby ensuring that the responses of HGFs (e.g. ECM remodelling) are in line with energy availability but are influenced by inflammatory context. For example, the presence of high concentrations of leptin in the inflamed gingiva (and hence a pro-inflammatory cytokine milieu) may synergistically drive HGF-mediated ECM degradation.
We conclude that leptin, in synergy with pro-inflammatory stimuli (IL-1 and the TLR-2 agonist pam2CSK4) selectively enhances MMP-1 and MMP-3 secretion in HGFs and suggest that gingival fibroblast-mediated ECM degradation, may be deleteriously enhanced during conditions of hyperleptinaemia (e.g. obesity, type 2 diabetes mellitus, exogenous leptin therapy).

**Acknowledgments**

We thank Dr John Meechan for provision of clinical tissue, and Dr Katrin Jaedicke and Dr Phil Williams for reading the manuscript and helpful discussions.

**Author Contributions**

Conceived and designed the experiments: RW AR PP JT. Performed the experiments: RW AS ST. Analyzed the data: RW AS ST AR PP JT. Contributed reagents/materials/analysis tools: AS ST. Wrote the paper: RW AR PP JT.

**References**

1. Bartold PM, Narayanan AS. (2006) Molecular and cell biology of healthy and diseased periodontal tissues. Periodontol 2000 40: 29–49.
2. Page-McCaw A, Ewald AJ, Werb Z. (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221–233. PMID: 17318226
3. Nagase H, Visse R, Murphy G. (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562–573. PMID: 16405877
4. Darveau RP. (2010) Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol 8: 481–490. doi: 10.1038/nrmicro2337 PMID: 20514045
5. Bodet C, Andrian E, Tanabe S-i, Grenier D. (2007) Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: A potential role in connective tissue destruction. Journal of Cellular Physiology 212: 189–194. PMID: 17299802
6. Sukkar TZ, Thomason JM, Cawston TE, Lakey R, Jones D, Catterall J, et al. (2007) Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines. J Periodontal Res 42: 580–588. PMID: 17956473
7. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, et al. (2012) Periodontitis and diabetes: a two-way relationship. Diabetologia 55: 21–31. doi: 10.1007/s00125-011-2342-y PMID: 22057194
8. Taylor JJ, Preshaw PM, Lalla E. (2013) A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Periodontol 84: S113–134. doi: 10.1902/jop.2013.134005 PMID: 23631573
9. Gregor MF, Hotamisligil GS. (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29: 415–445. doi: 10.1146/annurev-immunol-031210-101322 PMID: 21219177
10. Iwayama T, Yanagita M, Mori K, Sawada K, Ozasa M, Kubota M, et al. (2012) Adiponectin regulates functions of gingival fibroblasts and periodontal ligament cells. J Periodontal Res 47: 563–571. doi: 10.1111/j.1600-0765.2012.01467.x PMID: 22339094
11. Myers MG, Cowley MA, Munzberg H. (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70: 537–556. PMID: 17937601
12. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. (2010) Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152: 93–100. doi: 10.7326/0003-4819-152-2-201001190-00008 PMID: 20883828
13. Matarese G, Moschos S, Mantzoros CS. (2005) Leptin in immunology. J Immunol 174: 3137–3142. PMID: 15749839
14. Ay ZY, Kirzioglu FY, Tonguc MO, Sutcu R, Kapucuoglu N. (2012) The gingiva contains leptin and leptin receptor in health and disease. Odontology 100: 222–231. doi: 10.1007/s10266-011-0043-0 PMID: 22002746
|   | Reference                                                                                                                                  |
|---|------------------------------------------------------------------------------------------------------------------------------------------|
| 15| Park H, Kim J, Cha J, Bak E, Yoo Y. (2013) Induction of IL-6 and IL-8 expression by leptin treatment in periodontal ligament cells and gingival fibroblasts. Int J Oal Biol 38: 73–80. |
| 16| Milner JM, Rowan AD, Cawston TE, Young DA. (2006) Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther 8: R142. PMID: 16919164 |
| 17| Mahanonda R, Sa-Ard-Iam N, Montreecakon P, Pimkhoakham A, Yongvanichit K, et al. (2007) IL-8 and IDO expression by human gingival fibroblasts via TLRs. J Immunol 178: 1151–1157. PMID: 17202739 |
| 18| Hui W, Litherland GJ, Elias MS, Kitson GI, Cawston TE, Rowan AD, et al. (2012) Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis 71: 455–462. doi: 10.1136/annrheumdis-2011-200372 PMID: 22072016 |
| 19| Morandini AC, Chaves Souza PP, Ramos-Junior ES, Souza Costa CA, Santos CF. (2013) MyD88 or TRAM knockdown regulates interleukin (IL)-6, IL-8, and CXCL12 mRNA expression in human gingival and periodontal ligament fibroblasts. J Periodontol 84: 1353–1360. doi: 10.1902/jop.2012.120496 PMID: 23136947 |
| 20| Minami T, Kuroishi T, Ozawa A, Shimauchi H, Endo Y, Sugawara S. (2007) Histamine amplifies immune response of gingival fibroblasts. J Dent Res 86: 1083–1088. PMID: 17959901 |
| 21| Johnson WE, Li C, Rabinovic A. (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118–127. PMID: 16632515 |
| 22| Leek JT, Storey JD. (2007) Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 3: 1724–1735. PMID: 17907809 |
| 23| Yuan JS, Reed A, Chen F, Stewart CN Jr. (2006) Statistical analysis of real-time PCR data. BMC Bioinformatics 7: 85. PMID: 16504059 |
| 24| Ruwanpura SM, Noguchi K, Ishikawa I. (2004) Prostaglandin E2 regulates interleukin-1beta-induced matrix metalloproteinase-3 production in human gingival fibroblasts. J Dent Res 83: 260–265. PMID: 14981131 |
| 25| Cox SW, Eley BM, Killi M, Asikainen A, Tervahartiala T, Sorsa T. (2006) Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis 12: 34–40. PMID: 16390466 |
| 26| Koskinen A, Vuolteenaho K, Nieminen R, Moilanen T, Moilanen E. (2011) Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol 29: 57–64. PMID: 21342593 |
| 27| Herath TD, Wang Y, Seneviratne CJ, Darveau RP, Wang CY, Jin L. (2013) The expression and regulation of matrix metalloproteinase-3 is critically modulated by Porphyromonas gingivalis lipopolysaccharide with heterogeneous lipid A structures in human gingival fibroblasts. BMC Microbiol 13: 73. doi: 10.1186/1471-2180-13-73 PMID: 23548063 |
| 28| Souza PP, Palmqvist P, Lundgren I, Lie A, Costa-Neto CM, Lundberg P. (2010) Stimulation of IL-6 cytokines in fibroblasts by toll-like receptor 2. J Dent Res 89: 802–807. doi: 10.1177/0022034510366898 PMID: 20505053 |
| 29| Morandini AC, Chaves Souza PP, Ramos-Junior ES, Brozoski DT, Sipert CR, Souza Costa CA, et al. (2013) Toll-like receptor 2 knockdown modulates interleukin (IL)-6 and IL-8 but not stromal derived factor-1 (SDF-1/CXCL12) in human periodontal ligament and gingival fibroblasts. J Periodontol 84: 535–544. doi: 10.1902/jop.2012.120177 PMID: 22680301 |
| 30| Schram K, Ganguly R, No EK, Fang X, Thong FS, Sweeney G. (2011) Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration. Endocrinology 152: 2037–2047. doi: 10.1210/en.2010-1166 PMID: 21385940 |
| 31| Coppari R, Bjorbaek C. (2012) Leptin revisited: Its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 11: 692–708. doi: 10.1038/nrd3757 PMID: 22935803 |
| 32| Domeij H, Yucel-Lindberg T, Modeer T. (2002) Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. Eur J Oral Sci 110: 302–306. PMID: 12206592 |
| 33| Kida Y, Kobayashi M, Suzuki T, Takeshita A, Okamatsu Y, Hanazawa S, et al. (2005) Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 29: 159–168. PMID: 15652448 |
| 34| Barchowsky A, Frleta D, Vincenti MP. (2000) Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 12: 1469–1479. PMID: 11023661 |
35. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, et al. (2006) Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25: 1195–1204. PMID: 16205632

36. Wisler BA, Dennis JE, Malemud CJ. (2011) New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory/autoimmune disorders. Curr Signal Transduct Ther 6: 279–291.

37. Shi M, Lin TH, Appell KC, Berg LJ. (2008) Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28: 763–773. doi: 10.1016/j.immuni.2008.04.016 PMID: 18549798

38. Murray PJ. (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178: 2623–2629. PMID: 17312100

39. Litherland GJ, Dixon C, Lakey RL, Robson T, Jones D, Young DA, et al. (2008) Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3-kinase/Akt signaling-dependent. J Biol Chem 283: 14221–14229. doi: 10.1074/jbc.M710136200 PMID: 18332138

40. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. (2006) Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 38: 306–321. PMID: 16938801

41. Kiili M, Cox SW, Chen HY, Wahlgren J, Maisi P, Eley BM, et al. (2002) Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol 29: 224–232. PMID: 11940142

42. Chen YE. (2004) MMP-12, an old enzyme plays a new role in the pathogenesis of rheumatoid arthritis? Am J Pathol 165: 1069–1070. PMID: 15466374

43. Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, Maciver NJ. (2014) Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol 192: 136–144. doi: 10.4049/jimmunol.1301158 PMID: 24273001